Magzter GOLD ile Sınırsız Olun
Sadece 9.000'den fazla dergi, gazete ve Premium hikayeye sınırsız erişim elde edin
Denemek ALTIN - Özgür
MDC's decision to reject Dr Reddy's plea on Omaze ODT accepted
Chronicle Pharmabiz
|August 21, 2025
THE National Pharmaceutical Pricing Authority (NPPA) has accepted the recommendation of its Multidisciplinary Committee (MDC) of Experts to reject an application of Dr Reddy's Laboratories seeking special price for omeprazole delayed release orally disintegrating tablet of a certain dosage strength.
The company applied for grant of separate price of Rs. 17.90 per tablet without Goods and Services Tax (GST) for omeprazole delayed release orally disintegrating tablet 20 mg under the brand name Omez ODT, under the provision of DPCO, 2013, from the Rs 4.42 per tablet price fixed on March 27, 2025.
The MDC, which advises the NPPA in drug pricing in the country, in a meeting held on July 3, 2025 rejected the application of Dr Reddy's Laboratories observing that the application does not fall in the purview of Para 11(3) of the DPCO, 2013.
Bu hikaye Chronicle Pharmabiz dergisinin August 21, 2025 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Chronicle Pharmabiz'den DAHA FAZLA HİKAYE
Chronicle Pharmabiz
Devices sector raises concern over notification proposing fee for tests
THE medical devices industry has raised concern over the Department of Health and Family Welfares' draft notification introducing fee for test or evaluation of medical devices and mandating inclusion of licence number of sub contractor on the product labels. The Department published the draft notification on April 10, proposing various amendments to the Medical Devices Rules (MDR), 2017 including introduction of fee for test or evaluation of 11 types of tests or evaluation.
2 mins
April 30, 2026
Chronicle Pharmabiz
Panel asks DoP to take efforts to decrease imported content in medical devices
OBSERVING that a majority of the medical devices market is addressed by imports, the Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceuticals (DOP) to take measures including promotion of stronger collaboration among the industry, academic institutions and research organisations to accelerate indigenous development of advanced medical devices.
1 mins
April 30, 2026
Chronicle Pharmabiz
AI in endoscopy will improve detecting early-stage cancer markers
INDIA has been moving steadily towards better cancer care. However, many cancers in India are still detected late, especially those in the digestive system.
2 mins
April 30, 2026
Chronicle Pharmabiz
Telangana appoints DG of DCA as compounding authority
IN a significant move to streamline regulatory compliance under the newly enacted Jan Vishwas provisions, the Government of Telangana has officially designated the Director General (DG) of the state’s Drugs Control Administration (DCA), Shahnawas Quasim, as the 'Compounding Authority'.
2 mins
April 30, 2026
Chronicle Pharmabiz
AIOCD seeks PM's intervention against e-pharmacies
THE All India Organisation of Chemists & Druggists (AIOCD), representing over 12.40 lakh pharmacists and distributors, has formally petitioned Prime Minister Narendra Modi to intervene against the unregulated growth of e-pharmacies and predatory pricing by large corporate entities.
1 mins
April 30, 2026
Chronicle Pharmabiz
Shed The Cavalier Attitude
A Parliamentary Panel has recently asked the Department of Pharmaceuticals (DoP) to take corrective steps to remove any administrative and procedural delays related to the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme.
2 mins
April 30, 2026
Chronicle Pharmabiz
DCOIWA slams new DCGI recruitment rules, cites dilution of tech standards
THE Drugs Control Officers (I) Welfare Association (DCOIWA), the national body of drug regulatory officers in the country, has criticised the Union Heath Ministry's newly notified recruitment rules for the post of DCGI, labelling them as a serious policy lapse.
1 mins
April 30, 2026
Chronicle Pharmabiz
Experts highlight the need for data exclusivity to protect MSMES
EXPERTS have highlighted the need for clinical data exclusivity in order to protect MSME drug innovators in India.
2 mins
April 30, 2026
Chronicle Pharmabiz
Mid-sized hospitals in Tier-2 cities stranded in a financial vacuum: Expert
MID-sized hospitals in Tier-2 cities are currently trapped in a financial vacuum. This is because funding usually arrives either too early as venture capital or too late as a financial buyout, said Rakshith Rangarajan, equity fund manager, Inviga Investment Advisors.
2 mins
April 30, 2026
Chronicle Pharmabiz
Indian healthcare sector faces escalating cyber risks
INDIAN healthcare sector is confronting a surge in cyber threats as increasingly complex hospital IT ecosystems create multiple vulnerabilities for potential breaches.
2 mins
April 30, 2026
Listen
Translate
Change font size